Connect with us

Hi, what are you looking for?

World News

China retaliates against S.Korea, Japan over COVID restrictions

BEIJING — China began retaliating on Tuesday against South Korea and Japan, two of the countries which have imposed COVID-19 curbs on travelers from China, the last major economy to reopen its borders after three years of isolation.

China’s embassy in Seoul said it has suspended the issuance of short-term visas for visitors from South Korea. Japan’s Kyodo news agency reported that Beijing has imposed similar measures against Japan.

China reopened its borders on Sunday, removing the last major restriction that was part of a “zero-COVID” regime which it abruptly began dismantling in early December after historic protests against the curbs.

The frequent lockdowns, relentless testing and various other movement curbs since early 2020 have brought the world’s second-largest economy to one of its slowest growth rates in nearly half a century and caused widespread distress.

With the virus let loose, China has stopped publishing daily infection tallies. It has been reporting five or fewer deaths a day since the policy U-turn, figures that have been disputed by the World Health Organization and are inconsistent with funeral homes reporting a surge in demand for their services.

The United States, South Korea, France and others introduced testing requirements in response to China’s COVID outbreak.

Some governments have raised concerns about Beijing’s transparency over the scale and impact of its outbreak, as international experts predict at least 1 million deaths in China this year. Washington has also raised concerns about future potential mutations of the virus.

Although Beijing also demands negative COVID test results from anyone landing in China, officials last week threatened retaliation against countries mandating tests for people coming from China.

China’s embassy in Seoul said on its official WeChat account it will adjust its latest visa rules subject to the lifting of South Korea’s “discriminatory entry restrictions” against China.

China has also told travel agencies that it has stopped issuing new visas in Japan, Kyodo said, quoting multiple travel industry sources.

China has dismissed criticism over its data as politically-motivated attempts to smear its “success” in handling the pandemic and said any future mutations are likely to be more infectious but less harmful.

State media on Tuesday continued to downplay the severity of the outbreak.

An article in Health Times, a publication managed by People’s Daily, the Communist Party’s official newspaper, quoted several officials as saying infections have been declining in the capital Beijing and several Chinese provinces.

Kan Quan, director of the Office of the Henan Provincial Epidemic Prevention and Control, said the infection rate in the central province of 100 million people was nearly 90% as of Jan. 6.

Yin Yong, acting mayor of Beijing, said the capital was also past its peak. Li Pan, deputy director of the Municipal Health Commission in the city of Chongqing said the peak there was reached on Dec. 20.

In the province of Jiangsu, the peak was reached on Dec. 22, while in Zheijiang province “the first wave of infections has passed smoothly,” officials said. Two cities in the southern Guangdong province, China’s manufacturing heartland, reached their peaks before the end of the year.

Financial markets looked through the latest border curbs as mere inconvenience, with the yuan hitting a nearly five-month high on Tuesday.

Although daily flights in and out of China are still a tenth of pre-COVID levels for the moment, businesses across Asia, including South Korean and Japanese shop owners, Thai tour bus operators and K-pop groups are licking their lips at the prospect of more Chinese tourists.

Spending abroad by Chinese shoppers was a $250 billion a year market before COVID.

The retaliation against South Korea and Japan was not the only COVID conflict brewing in China.

State media has also taken a swipe at Pfizer Inc. over the price for its COVID treatment Paxlovid.

“It is not a secret that US capital forces have already accumulated quite a fortune from the world via selling vaccines and drugs, and the US government has been coordinating all along,” nationalist tabloid Global Times said in an editorial.

Pfizer’s Chief Executive Albert Bourla said on Monday the company was in discussions with Chinese authorities about a price for Paxlovid, but not over licensing a generic version in China.

The abrupt change of course in COVID policies has caught many hospitals ill-equipped, while smaller cities were left scrambling to secure basic anti-fever drugs.

Yu Weishi, chairman of Youcare Pharmaceutical Group, told Reuters his firm boosted output of its anti-fever drugs five-fold to one million boxes a day in the past month.

Wang Lili, general manager at another pharmaceutical firm, CR Double Crane, told Reuters that intravenous drips were their most in-demand product.

The company has since Jan. 5 done away with weekends to meet demand.

“We are running 24/7,” Wang said. — Reuters

    You May Also Like


    The head of the International Monetary Fund has warned of increased risks to the stability of the financial system after weeks of banking sector...


    1.22 billion people use Instagram every month. That’s a huge number of Instagrammers trying to hit it big on the platform all at the...


    Since the rise of online casinos, cybersecurity has become a major concern for both casino operators and players alike. The transactions that go around...


    The Home Office has made next to no progress in tackling criminal fraud during the past five years, despite it having become Britain’s most...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2023 | All Rights Reserved